CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published ahead of print on August 16, 2007
Clinical Journal of the American Society of Nephrology
© 2007 American Society of Nephrology
doi: 10.2215/CJN.01180307
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.01180307v1
2/5/932    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cravedi, P.
Right arrow Articles by Remuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cravedi, P.
Right arrow Articles by Remuzzi, G.

Received March 9, 2007
Accepted on June 19, 2007

ORIGINAL ARTICLES

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

Paolo Cravedi *{dagger}, Piero Ruggenenti *{dagger}1, Maria Chiara Sghirlanzoni {dagger}, and Giuseppe Remuzzi *{dagger}

*Clinical Research Centre for Rare Diseases "Aldo e Cele Daccò," Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, and {dagger}Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy


1 To whom correspondence should be addressed. E-mail: manuelap{at}marionegri.it.


  Abstract

Background and Objectives: Rituximab, given in four weekly doses, is a promising treatment for idiopathic membranous nephropathy and other immune-mediated diseases and lymphoproliferative disorders. This multidose regimen, however, may cause hypersensitivity reactions and is extremely expensive. This study was aimed at evaluating whether titrating rituximab to circulating CD20 B cells may improve safety and limit costs of treatment.


This article has been cited by other articles:


Home page
 CJASNHome page
F. C. Fervenza
Overcoming Calcineurin Dependence in Membranous Nephropathy: Is Rituximab the Answer?
Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1017 - 1019.
[Full Text] [PDF]

Home page
 CJASNHome page
A. Segarra, M. Praga, N. Ramos, N. Polanco, I. Cargol, E. Gutierrez-Solis, M. R. Gomez, B. Montoro, and J. Camps
Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent Patients
Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1083 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
A. S. Bomback, V. K. Derebail, J. G. McGregor, A. V. Kshirsagar, R. J. Falk, and P. H. Nachman
Rituximab Therapy for Membranous Nephropathy: A Systematic Review
Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 734 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D E Furst, E C Keystone, B Kirkham, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, G R Burmester, J Braun, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii2 - iii25.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Coppo
Non-steroidal and non-cytotoxic therapies for nephrotic syndrome
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1793 - 1796.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Society of Nephrology.